E. V. BARNETT, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: I wish to contradict the pessimistic impression placed on combination therapy and to emphasize that there is a great deal of anecdotal and controlled data supporting a clinical synergism for corticosteroids and cytotoxic drugs. We all agree that their use should continue to be investigational. I emphasize that the investigational design should include dosage schedules that avoid the toxic effects of both drugs and not include patients with persistent uremia. Your journal's recent reports (1, 2) and accompanying editorial (3) on the immunosuppressive therapy in lupus erythematosus fail to explain the improved survival of patients treated in
BARNETT EV. Lupus Erythematosus: Immunosuppressive Therapy. Ann Intern Med. ;84:610. doi: 10.7326/0003-4819-84-5-610_1
Download citation file:
Published: Ann Intern Med. 1976;84(5):610.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use